You are here: Industry Insights > Novartis

News List

Reeling from Cohen scandal, Novartis recruits Siemens veteran as new ethics chief fiercepharma
August 15, 2018
Rebuilding Novartis’ reputation is a top priority for CEO Vas Narasimhan after a series of kickback revelations around the world culminated in a full-blown political scandal in the U.S.—and he's brought in a new ethics policeman to help him do it.
A new era for migraine patients cphi-online
August 07, 2018
EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.
CAR-T player Cellectis poaches Stefan Scherer from Novartis fiercebiotech
August 06, 2018
Cellectis has named Stefan Scherer, M.D., Ph.D., as its SVP of clinical development. Scherer joins the off-the-shelf CAR-T pioneer from Novartis, where he headed up U.S. oncology early development and strategy.
Novartis hands over global rights for two oncology drugs to Shanghai's Laekna pharmafile
August 03, 2018
Novartis has revealed that it has jettisoned two of its clinical stage oncology products along with exclusive global development and commercialisation rights to Shanghai-based biotech firm Laekna.
Novartis partners with Albumedix to explore albumin drug delivery platform fiercebiotech
August 02, 2018
Novartis will partner with Albumedix, a U.K-based specialist in recombinant human albumin, to explore using the company’s technology as a possible drug delivery platform for several therapies.
Novartis licenses out unwanted GlaxoSmithKline cancer drugs to Chinese biotech fiercebiotech
August 02, 2018
Novartis has penned a pact with Shanghai-based biotech Laekna that will see it work on a pair of oral pan-Akt kinase inhibitors.
Novartis' migraine drug gets EMA approval pharmatimes
August 01, 2018
The EMA has approved Norvartis’ Aimovig (erenumab), making it Europe’s first treatment specifically designed to prevent migraine.
Novartis links with Medidata’s Shyft to strengthen its digital push fiercebiotech
July 31, 2018
Pharma giant Novartis has signed Shyft, a Medidata Solutions subsidiary, to help strengthen its digital solutions to aid the launch of new therapies targeted for the European market.
Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals? fiercepharma
July 30, 2018
Even though Amgen and Novartis rolled out their hot new migraine drug, Aimovig, at a lower-than-expected price of $6,900, the companies expected pushback from payers, and they prepared for that by handing out a lot of the product for free.
Novartis nabs much-needed new nod for slow-growing breast cancer drug Kisqali fiercepharma
July 27, 2018
Less than one day after Novartis CEO Vas Narasimhan talked up a potential key approval for lagging breast cancer drug Kisqali, the company has that approval in hand.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page